Drew Pardoll
Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (28)
Immunotherapies have transformed cancer care; however, tumor intrinsic and extrinsic factors contribute to high variability in therapeutic responses. While tissue injuries can impact cancer recurrence and metastatic spread, little is known about their potential to effect immune checkpoint blockade (ICB) response. In this study, we reveal that distal traumatic muscle injury accelerated progression and impaired adjuvant ICB response of multiple murine tumors. This injury-induced accelerated tumor growth coincided with decreased intra-tumoral density and effector phenotype of tumor-reactive CD8 + T cells and relied on communication through a shared draining lymph node. Enhancing injury repair using a biological scaffold abrogated the injury-induced accelerated tumor growth in an interleukin-4-dependent manner and improved ICB response. In a retrospective cohort analysis of breast cancer patients undergoing ICB treatment, biological scaffold implantation following mastectomy was associated with increased overall survival. This work suggests that injury-driven immune dysfunction may contribute to cancer progression and ICB resistance, but enhancing wound healing with pro-regenerative biomaterials may offer a viable strategy for mitigating adverse cancer outcomes, particularly in the setting of adjuvant and neoadjuvant ICB.
Year:
2026
Fibrosis plays a key role in both chronic disease progression and failure of synthetic biomaterial implants. However, the contribution of adaptive immunity to fibrotic development remains incompletely understood, particularly for regulatory T cells (Tregs). Here, we used single-cell multiomic profiling, integrating transcriptomics with T cell receptor (TCR) sequencing, to map Treg heterogeneity and clonal dynamics in a synthetic material-induced model of fibrosis. We uncovered progressive Treg clonal expansion accompanied by TCR activation signatures and an increasingly immunosuppressive phenotype along a continuous transcriptional trajectory. These Tregs suppressed immune responses and influenced extracellular matrix and vascular gene expression. Cell-cell communication inference predicted Treg-driven activation of pro-fibrotic and vasculogenic transcriptional programs in fibroblasts and endothelial cells, including Sox-family transcription factors. Functional Treg depletion increased inflammation and significantly reduced neovascularization. Together, these findings identify Treg functions in the fibro-vascular niche through stromal cell modulation, highlighting immune-stromal interactions as an important axis in fibrosis.
Year:
2026
Therapeutic biological scaffolds promote tissue repair primarily through the induction of type 2 immunity. However, systemic immunological factors, including aging, sex, and previous infections, can modulate this response. The gut microbiota is a well-established modulator of immune function across organ systems, yet its influence on type 2-mediated repair remains underexplored. Here, we establish a bidirectional relationship between the gut microbiota and biological scaffold-mediated tissue repair. Utilizing a conventionalized germ-free mouse, we demonstrate that scaffold implantation induces compositional and functional changes in the gut microbiome, particularly affecting amino acid biosynthesis. Additionally, in a model of antibiotic-induced microbiota depletion, we show that dysbiosis disrupts key immune regulators of type 2 immunity, including reductions in eosinophils, proregenerative macrophages, and interleukin-4 (IL-4)-producing CD4 + T cells. At 6 wk post–scaffold implantation, we observed a significant decrease in myocytes with centrally located nuclei alongside an upregulation in profibrotic gene expression with antibiotic treatment. These findings provide insights into the influence of the gut microbiota on type 2-mediated tissue repair.
Year:
2025
Supplementary Figure 5. Best radiographic response to relatlimab and nivolumab in patients with microsatellite stable colorectal cancer stratified by pre-treatment cytotoxic T cell (A) and Treg (B) density.
Year:
2025
Through natural or synthetic lineage barcodes, single-cell technologies now enable the joint measurement of molecular states and clonal identities, providing an unprecedented opportunity to study cell fate and dynamics. Yet, most computational methods for inferring cell development and differentiation rely exclusively on transcriptional similarity, overlooking the lineage information encoded by lineage barcodes. This limitation is exemplified by T cells, where subtle transcriptional differences mark divergent fates with distinct biological activity. Single-cell RNA and matched TCR sequencing is now ubiquitous in the analysis of clinical samples, where the TCR sequence provides an endogenous clonal barcode and could reveal clonal T cell responses. We present Clonotrace, a computational framework that jointly models gene expression and clonotype information to infer cell state transitions and fate biases with higher fidelity. While motivated by challenges in analyzing T cell populations, especially in the tumor microenvironment and immunotherapy settings, Clonotrace is broadly applicable to any lineage-barcoded single-cell dataset. Across diverse systems including T cells, hematopoietic differentiation, and cancer therapy resistance models, Clonotrace reveals differentiation hierarchies, distinguishes unipotent from multipotent states, and identifies candidate fate-determining genes driving lineage commitment.
Year:
2025
Supplementary Figure 5. Best radiographic response to relatlimab and nivolumab in patients with microsatellite stable colorectal cancer stratified by pre-treatment cytotoxic T cell (A) and Treg (B) density.
Year:
2025
Purpose: Combined inhibition of lymphocyte-activation gene 3 (LAG-3) and PD-1 improves outcomes in patients with melanoma. Increased LAG-3 expression in colorectal cancer correlates with reduced survival. Higher mucin and PD-L1 expression in the mismatch repair–proficient (pMMR) colorectal cancer tumor microenvironment was associated with increased LAG-3 and retrospectively with prolonged progression-free survival upon PD-1 blockade. This led to the hypothesis that LAG-3/PD-1 inhibition would improve clinical outcomes in this pMMR colorectal cancer subset. Patients and Methods: NCT03642067 was a phase II study evaluating the combination of relatlimab (LAG-3 inhibitor) and nivolumab (PD-1 inhibitor) in patients with previously treated metastatic pMMR colorectal cancer. Patients were enrolled into one of three cohorts: A, mucin/PD-L1–high; B, mucin/PD-L1–low; or C, mucin/PD-L1 unselected. The primary endpoint for each cohort was the objective response rate. Results: We enrolled 59 evaluable patients; best treatment responses were partial response (3), stable disease (6), and progressive disease (50). Response rates did not differ significantly between cohorts. Subgroup analyses demonstrated that two of five patients with lung-only metastases had a partial response. Comparison of liver and lung metastases identified higher baseline dendritic cell densities in lung lesions. Nivolumab/relatlimab resulted in increased intratumoral cytotoxic T cells. Lower baseline intratumoral regulatory T cells and ADAM10 + cancer cells correlated with clinical response. Conclusions: This investigation did not reach its primary endpoint for any of the three treatment cohorts but does provide critical insight into the effects of combining nivolumab/relatlimab on the colorectal cancer tumor microenvironment and identifies subgroups that may derive greater benefit from this combination.
Year:
2025
Purpose: Co-mutations of the Kirsten rat sarcoma virus ( KRAS ) and serine / threonine kinase 11 ( STK11 ) genes in advanced non–small cell lung cancer (NSCLC) are associated with immune checkpoint blockade (ICB) resistance. Although neoadjuvant chemoimmunotherapy is now a standard-of-care treatment for resectable NSCLC, the clinical and immunologic impacts of KRAS and STK11 co-mutations in this setting are unknown. Experimental Design: We evaluated and compared recurrence-free survival of resectable KRAS -mutated NSCLC tumors, with or without co-occurring STK11 mutations, treated with neoadjuvant ICB. Single-cell transcriptomics was performed on tumor-infiltrating T cells from seven KRAS mut /STK11 wt tumors and six KRAS and STK11 co-mutated ( KRAS mut /STK11 mut ) tumors. Results: Relative to KRAS mut /STK11 wt tumors, KRAS mut /STK11 mut exhibited significantly higher recurrence risk. Single-cell transcriptomics showed enhanced oxidative phosphorylation with evidence of decreased prostaglandin E2 signaling and increased IL-2 signaling in CD8 + tumor-infiltrating lymphocytes (TIL) from KRAS mut /STK11 mut tumors, a finding that was mirrored in KRAS wt tumors that relapsed. TILs from KRAS mut /STK11 mut tumors expressed high levels of molecules associated with tumor residence, including CD39 and ZNF683 (HOBIT). Conclusions: These divergent T-cell transcriptional fates suggest that T-cell maintenance and residence may be detrimental to antitumor immunity in the context of neoadjuvant ICB for resectable NSCLC, regardless of KRAS mutation status. Our work provides a basis for future investigations into the mechanisms underpinning prostaglandin E2 signaling and IL-2 signaling as they relate to T-cell immunity to cancer and to divergent clinical outcomes in KRAS mut /STK11 mut NSCLC treated with neoadjuvant ICB.
Year:
2025
Purpose: Malignant peripheral nerve sheath tumors (MPNST) are aggressive soft-tissue sarcomas and the leading cause of mortality in individuals with neurofibromatosis type 1 (NF1). Despite many clinical trials, outcomes for patients with MPNST have remained stagnant, and most succumb to their disease; thus, novel therapeutic approaches are needed. A better understanding of the MPNST immune ecosystem will aid in the development of strategies to activate the immune system against the tumor. In this study, we profile the tumor immune microenvironment (TIME) in NF1-associated peripheral nerve sheath tumors (PNST) to discover insights on the role played by tumor-infiltrating immune cells in malignant transformation. Experimental Design: Using fresh and formalin-fixed paraffin-embedded tissue from patients diagnosed with NF1-PNST, we dissected the TIME through IHC, multiparameter flow cytometry, and comparative transcriptomic studies. Results: Immunophenotyping confirmed increased immune cell infiltration during malignant progression, with a predominance of infiltrating myeloid cells, particularly CD163 + tumor-associated macrophages (TAM). The T cells within MPNST exhibited signs of tumor activation, characterized by high programmed cell death 1 expression. Additionally, MPNST specimens demonstrated elevated levels of immunosuppressive TAM, with heightened PD-L1 expression. The proportion of CD163 + myeloid cells within the TIME correlated with poorer progression-free survival. Notably, loss of H3K27 trimethylation correlated with low immune cell infiltration in MPNST. Conclusions: Malignant transformation of NF1-PNST is characterized by an immunosuppressive microenvironment comprising TAM with high expression of PD-L1, which is associated with inferior outcomes. These findings suggest the clinical potential of immune-modulating therapeutics that can unleash an antitumor immune response.
Year:
2024
Regulatory T cells (Treg) are important players in the tumor microenvironment. However, the mechanisms behind their immunosuppressive effects are poorly understood. We found that CCR6–CCL20 activity in tumor-infiltrating Tregs is associated with greater glycolytic activity and ablation of Ccr6 reduced glycolysis and lactic acid production while increasing compensatory glutamine metabolism. Immunosuppressive activity toward CD8 + T cells was abrogated in Ccr6 −/− Tregs due to reduction in activation-induced glycolysis. Furthermore, Ccr6 −/− mice exhibited improved survival across multiple tumor models compared to wild-type mice and Treg and CD8 + T-cell depletion abrogated the improvement. In addition, Ccr6 ablation further promoted the efficacy of anti-PD-1 therapy in a preclinical glioma model. Follow-up knockdown of Ccl20 with siRNA also demonstrated improvement in antitumor efficacy. Our results unveil CCR6 as a marker and regulator of Treg-induced immunosuppression and identify approaches to target the metabolic determinants of Treg immunosuppressive activity.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (49)
Ross Donehower
Professor
Johns Hopkins University
Kevin Lin
Assistant Professor
University of Washington
Eric S Christenson
Assistant Professor of Oncology
Johns Hopkins University School of Medicine
Christine A Pratilas
Vice Chair for Pediatric Oncology
Johns Hopkins University School of Medicine
Maximilian F Konig
Director, Cellular Therapy Program (Autoimmunity)
Johns Hopkins University School of Medicine
Michael Pishvaian
Associate Professor
Johns Hopkins University
Daniel A. Laheru
Johns Hopkins University School of Medicine
Joshua Reuss
Assistant Professor of Medicine
-
Betty Tyler
Profeesor
Johns Hopkins University School of Medicine
franck housseau
Associate Professor
Johns Hopkins University School of Medicine
Nancy Zhang
Professor
University of Pennsylvania
Cynthia L. Sears
Johns Hopkins University School of Medicine
Carol D. Morris
Memorial Sloan Kettering Cancer Center
Calixto-Hope G Lucas
Johns Hopkins University School of Medicine
Shibin Zhou
Professor
Johns Hopkins University School of Medicine
Hao Wang
Johns Hopkins University
Kenneth Kinzler
Professor
Johns Hopkins University
Hongkai Ji
Professor
Johns Hopkins University Bloomberg School of Public Health
Chetan Bettegowda
Johns Hopkins University School of Medicine
Crystal L. Mackall
Stanford University School of Medicine
Khaled Sanber
Assistant Professor
The University of Texas MD Anderson Cancer Center
Jaishri Blakeley
Johns Hopkins University
Zhicheng Ji
Assistant Professor
Duke University School of Medicine
Jelani Zarif
Associate Professor
Johns Hopkins University
Janis M. Taube
Johns Hopkins University
Joscelyn C. Mejías
Assistant Professor
Georgia Institute of Technology
Rana Rais
Johns Hopkins University
Locke Davenport Huyer
Associate Professor
Dalhousie University
Srinivasan Yegnasubramanian
-
John M Gross
Associate Professor/ Bone and Soft Tissue
Johns Hopkins University School of Medicine
Brian Ladle
Assistant Professor of Oncology and Pediatrics
Johns Hopkins University School of Medicine
Ana De Jesus-Acosta
Johns Hopkins University
Fausto Rodriguez
University of California, Los Angeles
Valsamo Anagnostou
Alex Grass Professor of Oncology
Johns Hopkins University School of Medicine
Suman Paul
Johns Hopkins University
Tianbei Zhang
Johns Hopkins University
Bert Vogelstein
Johns Hopkins University School of Medicine
Stephany Y Tzeng
Associate Research Professor
Johns Hopkins University
Won Jin Ho
Johns Hopkins University School of Medicine
Adam Levin
Johns Hopkins University
Barbara S. Slusher
Johns Hopkins University School of Medicine
Jordan Garcia
Assistant Professor
Vanderbilt University Medical Center
Jonathan D. Powell
Johns Hopkins University School of Medicine
Patrick M. Forde
Trinity College Dublin
Elizabeth M. Jaffee
Johns Hopkins University School of Medicine
Jennifer H. Elisseeff
-
Jonathan Spicer
Professor of Surgery
McGill University
Allan Belzberg
Professor of Neurosurgery
Johns Hopkins University
Elana Fertig
Assistant Professor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Make your next move.
Prepare your application
Review drafts before you send them.